The estimated Net Worth of Abhay Joshi is at least $2.51 Milión dollars as of 14 March 2019. Abhay Joshi owns over 666 units of Revance Therapeutics Inc stock worth over $595,115 and over the last 9 years he sold RVNC stock worth over $0. In addition, he makes $1,909,900 as Chief Operating Officer a President - R&D and Product Operations at Revance Therapeutics Inc.
Sign up
Abhay Joshi RVNC stock SEC Form 4 insiders trading
Abhay has made over 3 trades of the Revance Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 666 units of RVNC stock worth $2,797 on 14 March 2019.
The largest trade he's ever made was exercising 666 units of Revance Therapeutics Inc stock on 14 March 2019 worth over $2,797. On average, Abhay trades about 80 units every 38 days since 2015. As of 14 March 2019 he still owns at least 90,443 units of Revance Therapeutics Inc stock.
You can see the complete history of Abhay Joshi stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Abhay Joshi biography
Dr. Abhay Joshi Ph.D. serves as Chief Operating Officer, President - R&D and Product Operations of the Company., is Chief Operating Officer of the Revance Therapeutics Inc. Dr. Joshi has served our Chief Operating Officer since December 2015. Dr. Joshi brings over twenty-five years of global experience as a pharmaceutical and biotechnology executive. From March of 2007 to December 2015, Dr. Joshi served as the President and Chief Executive Officer of Alvine Pharmaceuticals, Inc., a pharmaceutical company developing therapeutic products for the treatment of autoimmune and inflammatory diseases, where he was responsible for overseeing all aspects of the company’s business. Prior to Alvine Pharmaceuticals, he served as an Executive Vice President, Chief Technical Officer and member of the Executive Committee at CoTherix, Inc., which was acquired by Actelion Ltd in 2007. Prior to CoTherix, Dr. Joshi was the Vice President of Global Technical Operations, Specialty Pharmaceuticals at Allergan, Inc., where he was responsible for the company’s global biologics manufacturing operations for BOTOX® and its Latin America and Asia Pacific pharmaceutical operations, and held a series of senior management positions. Dr. Joshi currently serves on the board of directors of Genyous Biomed International and Sira Pharmaceuticals, Inc. Dr. Joshi received his BTech in Chemical Engineering from the Indian Institute of Technology, New Delhi, an MSE and a Ph.D. in Chemical Engineering from the University of Michigan, Ann Arbor, and an MBA from the University of California, Irvine.
What is the salary of Abhay Joshi?
As the Chief Operating Officer a President - R&D and Product Operations of Revance Therapeutics Inc, the total compensation of Abhay Joshi at Revance Therapeutics Inc is $1,909,900. There are 1 executives at Revance Therapeutics Inc getting paid more, with Mark Foley having the highest compensation of $17,190,400.
How old is Abhay Joshi?
Abhay Joshi is 57, he's been the Chief Operating Officer a President - R&D and Product Operations of Revance Therapeutics Inc since 2020. There are 8 older and 7 younger executives at Revance Therapeutics Inc. The oldest executive at Revance Therapeutics Inc is Robert Byrnes, 75, who is the Independent Director.
What's Abhay Joshi's mailing address?
Abhay's mailing address filed with the SEC is C/O REVANCE THERAPEUTICS, INC., 1222 DEMONBREUN STREET, SUITE 2000, NASHVILLE, TN, 37203.
Insiders trading at Revance Therapeutics Inc
Over the last 11 years, insiders at Revance Therapeutics Inc have traded over $29,070,398 worth of Revance Therapeutics Inc stock and bought 136,530 units worth $2,014,047 . The most active insiders traders include Vlad Coric, Julian S Gangolli a Angus C. Russell. On average, Revance Therapeutics Inc executives and independent directors trade stock every 31 days with the average trade being worth of $83,132. The most recent stock trade was executed by Erica Jordan on 16 April 2024, trading 2,392 units of RVNC stock currently worth $9,090.
What does Revance Therapeutics Inc do?
revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form
What does Revance Therapeutics Inc's logo look like?
Complete history of Abhay Joshi stock trades at Revance Therapeutics Inc
Revance Therapeutics Inc executives and stock owners
Revance Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Mark Foley,
President, Chief Executive Officer, Director -
Abhay Joshi,
Chief Operating Officer, President - R&D and Product Operations -
Tobin Schilke,
Chief Financial Officer -
Mark J. Foley,
CEO & Director -
Dustin Sjuts,
Chief Commercial Officer, Aesthetics & Therapeutics -
Dr. Abhay Joshi,
COO, Pres of R&D and Product Operations -
Dustin S. Sjuts,
Pres -
Tobin C. Schilke,
CFO & Principal Accounting Officer -
Chris Nolet,
Independent Director -
Jill Beraud,
Independent Director -
Angus Russell,
Independent Chairman of the Board -
Robert Byrnes,
Independent Director -
Philip Vickers,
Independent Director -
Phyllis Gardner,
Independent Director -
Julian Gangolli,
Independent Director -
Jeanie Herbert,
Sr. Director, Investor Relations -
Aubrey Rankin,
Director -
Dwight Moxie,
Senior Vice President, General Counsel, Corporate Secretary -
Azita Nejad,
Sr. VP of Technical Operations -
Justin Ford,
Sr. VP of HR & Head of People -
Taryn Conway,
VP of Marketing -
Jessica Serra,
Head of Investor Relations & ESG -
L Daniel Browne,
CEO and President -
James Walter Glasheen,
Director -
Ronald W Eastman,
Director -
Mark A Sr Prygocki,
Director -
Todd Erik Zavodnick,
CCO & President, -
Cyril Allouche,
Principal Accounting Officer -
Caryn Gordon Mc Dowell,
SVP, GC & Secretary -
Jacob Waugh,
Chief Scientific Officer -
Jonathan Tunnicliffe,
Director -
Ronald J Wooten,
Director -
Woodlands Health Ventures F...,
-
Arthur Peter Bertolino,
EVP and Chief Medical Officer -
Pharma Opportunities Fund I...,
-
Lauren P Silvernail,
CFO, Secretary & EVP Corp Dev. -
Curtis Ruegg,
EVP, Technical Operations -
Olivia C Ware,
Director -
Carey O Connor Kolaja,
Director -
Erica Jordan,
Chief Commercial Officer -
Vlad Coric,
Director